Rheumatoid Arthritis Clinical Trial
— T8Official title:
A Radomized, Double-blind, and Placebo-controlled Multicenter Clinical Trial of Hydroxytriptolide, in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Verified date | June 2017 |
Source | Shanghai Pharmaceuticals Holding Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to investigate the efficacy and safety of Hydroxytriptolide(LTS) in active rheumatoid arthritis patients with an inadequate response to methotrexate.
Status | Completed |
Enrollment | 120 |
Est. completion date | December 28, 2016 |
Est. primary completion date | April 30, 2015 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 35 Years to 65 Years |
Eligibility |
Inclusion Criteria: - 35-65 years old, female, postmenopausal, parous, nulliparous with no fertility requirements - 1987 ACR Diagnostic criteria or 2009 ACR/EULAR Diagnostic criteria. X ray of Evaluable Joint in phase I/II/III, Joint Function in Phase I/II/III - Active RA - Continuously taking MTX for at least three months, =7.5mg/week. Before first study dose, keep in stable MTX dose for at least 4 weeks - Keep in stable NSAIDs dose or low-dose glucocorticoids for at least 4 weeks before first study dose - Using non-prohibited combination therapy, keep in stable dose for at least 7 days before first study dose - Using DMARD should have appropriate withdrawal period: - Withdrawal for 4 weeks: Sulfasalazine, Azathioprine, Chloroquine, *Hydroxychloroquine, Auranofin, Penicillamine, Traditional Chinese medicine preparation(TGP, Sinomenine) - Withdrawal for 8 weeks: Leflunomide - Withdrawal for 8 weeks: Intramuscular, intravenous, intra-articular injection glucocorticoids - Women with fertility, negative in pregnancy test, and agreed to take contraceptive measures physical - Voluntary informed consent - Willing to follow the required regimen and schedule, follow-up examination Exclusion Criteria: 1. Currently suffering or have suffered from other inflammatory joint diseases, such as mixed connective tissue disease, scleroderma, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome, bone arthritis, rheumatoid arthritis, gouty arthritis, diagnosis of arthritis before 16yrs 2. With severe non-articular manifestations such as high fever, interstitial pneumonia, pleurisy, pericarditis, severe vasculitis, neuropathy, etc. 3. The evaluable joint underwent the surgical treatment within 2 months 4. Currently or recent have serious, or progression, or disease history not controled, including: liver, kidney, blood, gastrointestinal, endocrine, metabolic, respiratory, cardiovascular, nervous system diseases 5. Currently or have malignancy, lymphoproliferative disease history 6. Continuously use Tripterygium preparations for more than three months and have no effect 7. History of using TNF-a inhibitors of biological agents.(Adalimumab, infliximab, etanercept) 8. Severe or persistent infection within 3 months 9. X-ray shows active pulmonary infection 10. HBV, HCV, HIV, AIDS 11. WBC<4.0×10^9/L, PLT<100×10^9/L, Hb<85g/L 12. AST>2×ULN, ALT>2×ULN 13. Cr>135umol/L 14. Used oral contraceptive druds within 3 months 15. Pregnancy test was positive or lactating patients or patients with birth preparation 16. Have to use the prohibited drugs 17. With clinical symptoms of a serious history of drug abuse or alcohol abuse 18. History of any durg clinical trials within 3 months 19. Allergy to tripterygium 20. Other reasons depends by the investigator |
Country | Name | City | State |
---|---|---|---|
China | The first affiliated hospital of bengbu medical college | Bengbu | Anhui |
China | Changhai Hospital | Shanghai | Shanghai |
China | Changzheng Hospital | Shanghai | Shanghai |
China | Shanghai Jiaotong University School of Medicine, Renji Hospital Ethics Committee | Shanghai | Shanghai |
China | Zhongshan Hospital Fudan University | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Pharmaceuticals Holding Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in ACR 20 at 12 weeks and at 24 weeks | 12weeks, 24weeks | ||
Secondary | Change from baseline in DAS 28 at 12 weeks and at 24 weeks | 12weeks, 24weeks | ||
Secondary | The proportion of patients reached ACR50 at 12 weeks and 24 weeks | 12weeks, 24weeks | ||
Secondary | The proportion of patients reached ACR70 at 12weeks and 24weeks | 12weeks,24weeks | ||
Secondary | Change from baseline in swollen joint count at 12 weeks and 24 weeks | 12weeks,24weeks | ||
Secondary | Change from baseline in tender joint count at 12weeks and 24weeks | 12weeks,24weeks | ||
Secondary | Change from baseline in the duration of morning stiffness at 12 weeks and 24 weeks | 12 weeks and 24 weeks | ||
Secondary | Change from baseline in rest pain at 12 weeks and 24 weeks | 12weeks,24weeks | ||
Secondary | Change from baseline in PtGA patient global assessment at 12 weeks and 24 weeks | 12 weeks and 24 weeks | ||
Secondary | Change from baseline in PGA physician global assessment at 12 weeks and 24 weeks | 12 weeks and 24 weeks | ||
Secondary | Change from baseline in HAQ health assessment questionnaire at 12 weeks and 24 weeks | 12 weeks, 24 weeks | ||
Secondary | Change from baseline in CRP,ESR,RF,CCP at 12 weeks and 24 weeks | 12 weeks, 24 weeks | ||
Secondary | Change from baseline in IgA, IgG, IgM at 12 weeks and 24 weeks | 12 weeks, 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |